{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T03:48:32Z","timestamp":1784260112995,"version":"3.55.0"},"reference-count":46,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Therapy"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Herpes simplex virus 1 (HSV-1) affects a large part of the adult population. Anti-HSV-1 drugs, such as acyclovir, target thymidine kinase and viral DNA polymerase. However, the emerging of resistance of HSV-1 alerts for the urgency in developing new antivirals with other therapeutic targets. Thus, this study evaluated a series of 1,4-disubstituted-1,2,3-triazole derivatives against HSV-1 acute infection and provided deeper insights into the possible mechanisms of action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Human fibroblast cells (HFL-1) were infected with HSV-1 17 syn+ and treated with the triazole compounds at 50 \u03bcM for 24 h. The 50% effective drug concentration (EC\n                      <jats:sub>50<\/jats:sub>\n                      ) was determined for the active compounds. Their cytotoxicity was also evaluated in HFL-1 with the 50% cytotoxic concentration (CC\n                      <jats:sub>50<\/jats:sub>\n                      ) determined using CellTiter-Glo\n                      <jats:sup>\u00ae<\/jats:sup>\n                      solution. The most promising compounds were evaluated by virucidal activity and influence on virus egress, DNA replication and transcription, and effect on an acyclovir-resistant HSV-1 strain.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compounds 3 ( (E)-4-methyl-N\u2032-(2-(4-(phenoxymethyl)-1H-1,2,3-triazol1yl)benzylidene)benzenesulfonohydrazide) and 4 ( 2,2\u2032-(4,4\u2032-((1,3-phenylenebis(oxy))bis(methylene))bis(1H-1,2,3-triazole-4,1 diyl)) dibenzaldehyde) were the most promising, with an EC\n                      <jats:sub>50<\/jats:sub>\n                      of 16 and 21 \u03bcM and CC\n                      <jats:sub>50<\/jats:sub>\n                      of 285 and 2,593 \u03bcM, respectively. Compound 3 was able to inhibit acyclovir-resistant strain replication and to interfere with virus egress. Both compounds did not affect viral DNA replication, but inhibited significantly the expression of ICP0, ICP4 and gC. Compound 4 also affected the transcription of UL30 and ICP34.5.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings demonstrated that these compounds are promising antiviral candidates with different mechanisms of action from acyclovir and further studies are merited.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3851\/imp3387","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T11:45:56Z","timestamp":1615463156000},"page":"399-410","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":32,"title":["Antiviral Activity of 1,4-Disubstituted-1,2,3-Triazoles against HSV-1\n                    <i>in vitro<\/i>"],"prefix":"10.1177","volume":"25","author":[{"given":"Daiane J","family":"Viegas","sequence":"first","affiliation":[{"name":"LAMCIFAR, Laborat\u00f4rio de Modelagem Molecular e Pesquisa em Ci\u00eancias Farmac\u00eauticas, Universidade Federal do Rio de Janeiro, Maca\u00e9, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f4nica D","family":"da Silva","sequence":"additional","affiliation":[{"name":"Laborat\u00f4rio de S\u00edntese Org\u00e2nica, Pontif\u00edcia Universidade Cat\u00f4lica do Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla D","family":"Buarque","sequence":"additional","affiliation":[{"name":"Laborat\u00f4rio de S\u00edntese Org\u00e2nica, Pontif\u00edcia Universidade Cat\u00f4lica do Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Bloom","sequence":"additional","affiliation":[{"name":"College of Medicine, Department of Microbiology and Molecular Genetics, University of Florida, Gainesville, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula A","family":"Abreu","sequence":"additional","affiliation":[{"name":"LAMCIFAR, Laborat\u00f4rio de Modelagem Molecular e Pesquisa em Ci\u00eancias Farmac\u00eauticas, Universidade Federal do Rio de Janeiro, Maca\u00e9, Rio de Janeiro, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,11,1]]},"reference":[{"key":"bibr1-IMP3387","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.06.027"},{"key":"bibr2-IMP3387","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215487"},{"key":"bibr3-IMP3387","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00504-13"},{"key":"bibr4-IMP3387","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00097"},{"key":"bibr5-IMP3387","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2016.07.153"},{"key":"bibr6-IMP3387","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00324"},{"key":"bibr7-IMP3387","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10149-5"},{"key":"bibr8-IMP3387","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-180266"},{"key":"bibr9-IMP3387","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2010.01.001"},{"key":"bibr10-IMP3387","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890410503"},{"key":"bibr11-IMP3387","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010510-100228"},{"key":"bibr12-IMP3387","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.4.868"},{"key":"bibr13-IMP3387","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2004.04.002"},{"key":"bibr14-IMP3387","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.08.013"},{"key":"bibr15-IMP3387","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00615-10"},{"key":"bibr16-IMP3387","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.16.1.114-128.2003"},{"key":"bibr17-IMP3387","doi-asserted-by":"publisher","DOI":"10.1038\/ijos.2016.3"},{"key":"bibr18-IMP3387","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.09.010"},{"key":"bibr19-IMP3387","doi-asserted-by":"publisher","DOI":"10.3851\/IMP3018"},{"key":"bibr20-IMP3387","doi-asserted-by":"publisher","DOI":"10.1007\/s00044-013-0762-6"},{"key":"bibr21-IMP3387","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2017.05.014"},{"key":"bibr22-IMP3387","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2011.02.007"},{"key":"bibr23-IMP3387","doi-asserted-by":"publisher","DOI":"10.2174\/1573406413666170307165236"},{"key":"bibr24-IMP3387","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-020-10094-2"},{"key":"bibr25-IMP3387","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2018.10.003"},{"key":"bibr26-IMP3387","doi-asserted-by":"publisher","DOI":"10.1039\/C0CC02472D"},{"key":"bibr27-IMP3387","doi-asserted-by":"publisher","DOI":"10.1002\/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4"},{"key":"bibr28-IMP3387","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2005.10.111"},{"key":"bibr29-IMP3387","unstructured":"Promega. CellTiter-Glo\u00ae One solution Assay. Technical bulletin TB370. (Updated February 2016. Accessed 01 November 2017.) Available from www.promega.com\/products\/cell-health-assays\/cell-viability-andcytotoxicityassays\/celltiter_glo-one-solution-assay\/?catNum=G8461."},{"key":"bibr30-IMP3387","doi-asserted-by":"publisher","DOI":"10.1078\/094471103322331467"},{"key":"bibr31-IMP3387","doi-asserted-by":"publisher","DOI":"10.1021\/acs.iecr.6b04863"},{"key":"bibr32-IMP3387","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2011.02.007"},{"key":"bibr33-IMP3387","doi-asserted-by":"publisher","DOI":"10.5402\/2012\/760517"},{"key":"bibr34-IMP3387","first-page":"833","volume":"52","author":"Abdel-Hafez A.A.","year":"2002","journal-title":"Arzneimittelforschung"},{"key":"bibr35-IMP3387","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-369428-7.00037-9"},{"key":"bibr36-IMP3387","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.66.1.347"},{"key":"bibr37-IMP3387","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.64.8.3882-3894.1990"},{"key":"bibr38-IMP3387","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.7.6119-6130.1998"},{"key":"bibr39-IMP3387","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-74-4-607"},{"key":"bibr40-IMP3387","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03500-12"},{"key":"bibr41-IMP3387","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116527"},{"key":"bibr42-IMP3387","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-76-2-321"},{"key":"bibr43-IMP3387","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04638-9"},{"key":"bibr44-IMP3387","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.14.7329-7343.2004"},{"key":"bibr45-IMP3387","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.139.5.1137"},{"key":"bibr46-IMP3387","doi-asserted-by":"publisher","DOI":"10.1006\/meth.2001.1262"}],"container-title":["Antiviral Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3387","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3851\/IMP3387","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3851\/IMP3387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T12:52:59Z","timestamp":1777380779000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3851\/IMP3387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.3851\/IMP3387"],"URL":"https:\/\/doi.org\/10.3851\/imp3387","relation":{},"ISSN":["1359-6535","2040-2058"],"issn-type":[{"value":"1359-6535","type":"print"},{"value":"2040-2058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,1]]}}}